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Objective. 0e objective of this article is to provide a high-profile review and discussion on the study design and statistical analysis
of pivotal clinical trials conducted to demonstrate the safety and effectiveness of closed-loop investigational artificial pancreas
device systems (APDSs) in premarket approval applications. Methods. 0e United States Food and Drug Administration (FDA)
guidance on the content of investigational device exemption and premarket approval applications for APDSs is reviewed with
special emphasis on study design and statistical analysis of the pivotal clinical trials.0e two pivotal studies for theMiniMed 670G
hybrid closed-loop system by Medtronic in their premarket approval application are summarized and discussed. Results. 0e
United States FDA established detailed recommendations on the study design and statistical analysis of pivotal clinical trials for
the industry that seek market investigational APDSs and for FDA scientific reviewers that regulate the device applications. 0e
recommendations cover specifics regarding patient population, clinical endpoints, and strategies for data analysis. However, the
two pivotal studies that demonstrated the effectiveness of the FDA-approved MiniMed 670G hybrid closed-loop system were not
typical randomized controlled trials as per FDA recommendations.Conclusion.0e development and regulation of investigational
APDSs require careful and sophisticated clinical study designs and data analysis in premarket approval applications. 0e
regulatory evaluation process of the APDSs is rather complicated since the devices consist of multiple components that col-
laboratively function to mimic human pancreases.
1. Introduction
Diabetes mellitus is a chronic disease of the body’s regulation
of blood glucose levels. Proper regulation of blood glucose
levels is essential as glucose is an important energy source in
the body, especially for the brain. 0erefore, excess blood
glucose levels can lead to serious health problems [1, 2]. 0e
cause of the disease varies by type. Type I diabetes is when
the pancreas produces little or no insulin, the hormone that
allows for glucose to enter cells from the bloodstream,
leading to hyperglycemia [3]. Type I diabetes typically
manifests during childhood or adolescence, and it can de-
velop in adults. 0is form of the disease can have different
etiologies [4]. Type II diabetes mellitus occurs due to issues
in the body’s metabolism of glucose. It can either be due to
the body’s resistance to insulin or an inability to produce
enough insulin to maintain normal blood glucose levels [3].
0is form of the disease often develops slowly and is known
Hindawi
International Journal of Endocrinology
Volume 2021, Article ID 8812695, 6 pages
https://doi.org/10.1155/2021/8812695
as adult-onset diabetes, but it has become more common in
children over time.0ere are no cures for either disease type,
which is why the proper regulation of blood glucose levels is
imperative for patients [3]. 0e artificial pancreas device
system (APDS) is a device that can closely mimic a normally
functioning pancreas by administering insulin at a certain
threshold that can be maintained by sensing blood glucose
levels [5]. 0is device has a significant treatment capacity for
those with type I diabetes, as the artificial pancreas can
compensate for the loss of pancreatic function found inmost
affected patients.
Currently, the United States Food and Drug Adminis-
tration (FDA) guidance regarding APDS device approval [6]
focuses on the use of continuous glucose monitor data for
the evaluation of safety and effectiveness of the device while
allowing for flexibility regarding study endpoints, indica-
tion, study size, and duration in clinical trials. 0e guidance,
issued on November 9, 2012, details a clinical study pro-
gression that can be used by the sponsor for APDS evalu-
ation (the term “sponsor” is used throughout this article to
refer to either the manufacturers planning to market the
investigational device or the investigators planning clinical
research studies on the device). 0e guidance elaborates
recommendations for low-glucose suspend systems and
closed-loop control systems. Low-glucose suspend system,
otherwise known as threshold suspend, is a feature that
allows for an artificial pancreas device to automatically halt
insulin delivery when a low blood sugar threshold is reached
and to achieve full management of glucose levels.0e closed-
loop control system refers to an automatic control system
where the delivery of insulin through the device is managed
and regulated by feedback from an algorithm based on CGM
data [7]. 0e MiniMed 670G hybrid closed-loop system by
Medtronic [8] was the first second-generation, closed-loop
APDS approved by the FDA to automatically monitor
glucose and administer appropriate basal insulin doses in
people 14 years or older with type I diabetes.
0e development and regulation of an investigational
APDS device require careful and sophisticated clinical study
design and data analysis to demonstrate the device’s safety
and effectiveness. Because the APDS consists of multiple
components that collaboratively function to mimic human
pancreases, its evaluation process is complex. 0is article
reviews and discusses the FDA’s recommendations on the
clinical study design and statistical data analysis in the in-
vestigational device exemption (IDE) and premarket ap-
proval (PMA) applications for the APDS. We also examine
the pivotal clinical studies conducted and reported in the
PMA Summary of Safety and Effectiveness Data (SSED) for
the approval of the MiniMed 670G hybrid closed-loop
system [8] and consider the concordance between the study
design and statistical evidence used to the recommendations
in the FDA guidance.
2. Artificial Pancreas Device Systems
0ere are three main devices used by patients with diabetes
mellitus, which can be components of an APDS: (1) blood
glucose devices (BGDs) that determine blood glucose levels
from a finger-prick blood sample; (2) infusion pumps for
continuous subcutaneous insulin infusion (CSII); (3) con-
tinuous glucose monitoring (CGM) system, which has a
sensor that measures the concentration of glucose in the
interstitial fluid at consistent intervals. Furthermore, it is
essential to note that CGM systems are not fully adequate
substitutions for BGDs, but they allow for patients to track
the course of the glucose levels. However, while these devices
are greatly beneficial, it can still be a struggle for patients to
maintain blood glucose levels at optimal levels to prevent the
risk of hypoglycemia.
0e primary function of an APDS is to maintain blood
glucose concentrations at or near a specified range through
communication between a CGM and infusion pump to
automatically reduce or increase insulin infusion accord-
ingly.0ere are four aspects of APDS: (1) continuous glucose
monitor (CGM); (2) APDS computer-controlled algorithm;
(3) infusion pump; (4) the patient (see Figure 1). 0e CGM’s
sensor is placed subcutaneously and measures the glucose
levels in the interstitial fluid.0e CGMdisplays this data and
the direction and rate of change of the estimated glucose
levels. 0e CGM’s transmitter then sends all of this infor-
mation to a controller. It is also crucial that the CGM is
periodically calibrated with a BGD to ensure that it is
detecting themost accurate glucose levels.0e APDS control
algorithm then analyzes the data from the CGM in an ex-
ternal processor, the controller. 0e algorithm calculates the
dosing needed based on the current levels, and this infor-
mation is sent to the infusion pump.0e infusion pump then
delivers insulin to the subcutaneous tissue and adjusts the
dosage according to the received information. In all of this,
the patient plays a central role in the functioning of the
APDS. Blood glucose levels are ever-changing and fluctuate
according to the patient’s diet, activity level, and metabolism
capacity.
0ere are three main categories of APDS that are cur-
rently used: 0reshold Suspend Delivery System, Control-
to-Range (CTR) system, and Control-to-Target (CTT)
system [6]. 0e 0reshold Suspend Device System adjusts
insulin dosing only if the sensor value reaches a pre-
determined lower threshold of measured interstitial glucose.
However, this device does not take any action if the sensor
value is above the determined threshold. On the other hand,
the CTR system adjusts insulin levels to maintain a pre-
determined higher and lower threshold. At the same time, it
will not take any action when the glucose levels are within
the thresholds. With the use of either of these two devices,
patients should still monitor their blood glucose concen-
tration, set appropriate basal rates for the insulin pump, and
take premeal bolus insulin to maintain control of their
glucose levels. 0e CTT system is unique because it requires
no further interaction of the user beyond the CGM’s cali-
bration. 0e CTT system is fully automated to maintain set
target glucose levels at all times.
0ere are two CTR and CTTsystem subtypes depending
on what drug(s) is being delivered and how the drug affects
glucose concentrations: insulin-only system and bihormonal
control system [6, 7]. While an insulin-only system achieves
a target glucose level by increasing or decreasing insulin
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dosage, a bihormonal control system maintains thresholds
through the use of an APDS control algorithm(s) for the
infusion pump. 0is allows for the administration of insulin
to lower glucose levels and another hormone, such as glu-
cagon, to increase blood glucose levels. 0erefore, the
bihormonal control system mimics the regulation of blood
glucose levels by the pancreas more precisely than an in-
sulin-only system.
0e FDA guidance indicates that “the APDS is intended for
patients with type 1 diabetes for the subcutaneous infusion of
insulin and the continuous measurement of interstitial glucose
to aid in the management of their disease. 0e APDS auto-
matically adjusts insulin delivery in response to CGM values
that have exceeded or are predicted to exceed the bounds of a
prespecified blood glucose range. 0e APDS is intended to
assist the patients in managing their disease” [8].
3. Study Design and Data Analysis of Clinical
Studies for Investigating the Artificial
Pancreas Device Systems
3.1. Study Design of Pivotal Clinical Studies. 0e pivotal
clinical studies for an investigational APDS function to
collect data to support the device’s safety and effectiveness.
0ese studies should be performed with the final APDS
device for its actual use in a real-world environment. 0e
FDA recommends that sponsors compare clinical outcomes
between patients using a sensor-augmented pump control
device and patients using the APDS. It is suggested that the
control group uses currently available technology for there
to be a proper analysis of the new APDS’ technology and
algorithm. FDA advises that a robust pivotal clinical trial
design to validate an investigational APDS should be either a
randomized cross-over design or a randomized parallel
design in an outpatient setting. 0e standard of care should
be given to the patients in the control group by performing
finger stick blood glucose tests to determine proper therapy.
According to these results, the patients in the test group
should be treated by a systematic adjustment as directed by
the instructions of the APDS.
0e patient population in the pivotal clinical studies
should be selected according to the intended use of the
APDS device because the chosen study population can
largely influence the study design, sample size, duration of
follow-up, and final approved device indications. 0e FDA
recommends that sponsors consider these factors while
enrolling patients for the initial subject population: subjects
experienced with insulin pumps for more than 6 months,
subjects willing to perform more than 4 finger stick blood
glucose measurements daily, subjects willing to perform
manufacturer-required sensor calibrations, subjects willing
to wear the system more than 6 days per week, subjects
willing to keep a minimum log of sick days, days with ex-
ercise, or symptoms of low and high blood glucose episodes
and medications. Suppose sponsors aim to improve study
efficiency by reducing study sample size and study duration;
the study patients may be enriched by targeting subjects with
a high percentage HbA1c and frequent hypoglycemia despite
aggressive attempts at improved glycemic control, subjects
with purposeful maintenance of high HbA1c to avoid any
hypoglycemia, and subjects with frequent hypoglycemia.
Furthermore, the FDA recommends that subjects be older
than 18 years of age to ensure that patients can respond to
device problems. However, the FDA is also keen on pro-
moting the development of a safe and effective APDS for
subjects younger than 8 years of age.
Clinical study endpoints to evaluate the APDS perfor-
mance will mainly target CGM data, the measurement, or
estimation of blood glucose levels. 0erefore, the FDA de-
termines that it is acceptable and appropriate for CGM data
to be used to evaluate an investigational APDS. While
endpoints, indication for use, and intended marketing
claims will differ for each particular device, the endpoints
should numerically reflect the degree of the safety and ef-
fectiveness of the APDS. 0e FDA recommends measure-
ments of hypoglycemia and hyperglycemia, level of glycated
hemoglobin (HbA1c), or Time in Range (TIR) for potential
endpoints of these studies. In regard to hypoglycemia and
hyperglycemia, potential endpoints include “number of
hypoglycemic and hyperglycemic events or event rate; time
spent in hypoglycemia or low glycemic concentrations and
hyperglycemic or high glycemic concentration events; av-
erage duration for all hypoglycemic or low glycemic con-
centration events and hyperglycemic or high glycemic
concentration events; or mean area under the curve (AUC)
for all hypoglycemic events less than 70mg/dL and hy-
perglycemic events greater than 240mg/dL” [6]. Another
potential primary effectiveness endpoint is the level of
HbA1c, as it estimates the average glycemic exposure of red
blood cells over 90 days. 0e endpoint TIR that determines
how successful an APDS can keep glucose within a pre-
defined range can also be adopted as the primary effec-
tiveness endpoint in the pivotal clinical studies for the
APDSs. While assessing TIR, it is essential to also examine
the effect of the device on clinical symptoms, glucose values
above and below desired ranges, and examine the TIR in
relation to other glycemic control markers.
Figure 1: Artificial pancreas device system with four parts: (1)
continuous glucose monitor (CGM); (2) APDS computer-con-
trolled algorithm; (3) infusion pump; (4) the patient; (5) Blood
glucose devices (BGDs) are used to calibrate the CGM (this figure is
modified from [7]).
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0e safety endpoints for an investigational APDS should
be evaluated to ensure that the device does not increase the
incidence of severe hypoglycemia or severe hyperglycemia
or diabetic ketoacidosis. 0erefore, some safety endpoints
recommended by the FDA include “severe hyperglycemia
and elevated ketones; diabetic ketoacidosis; number of
CGM-defined hyperglycemic events; mean AUC above
240mg/dL as calculated from CGM readings; HbA1c above
a predefined accepted increase that may occur as a result of
reduction of hypoglycemia or from inappropriate pump
suspensions or decreased insulin delivery; percentage of
CGM readings in the higher hyperglycemic ranges; severe
hypoglycemia; number of CGM-defined hypoglycemic
events; mean AUC below 60 or 70mg/dL as calculated from
CGM readings; or percentage of CGM readings in the hy-
poglycemic range less than 60 or 70mg/dL” [6]. Other
potential endpoints, again based on the specific device and
its intended use, can include “incidence of catheter blockage
within each group; capillary blood glucose values above and
below the defined hypoglycemia and hyperglycemia
thresholds; fasting whole blood ketone concentrations
within each group, evaluating elevated beta-hydroxybutyrate
concentrations; glycemic variability; incidence, severity, and
timing of CGM-events for hypoglycemia and hyperglyce-
mia; safety and effectiveness subgroup analysis, such as for
pediatric subjects; quality of life; weighted mean AUC of
CGM-events for hypoglycemia and hyperglycemia” [6].
3.2. Data Analysis of Pivotal Clinical Studies. 0e FDA
recommends certain general considerations for data anal-
ysis, including patient demographics, medical history, and
other important baseline characteristics, summarized using
descriptive statistics and frequency tables as appropriate. It is
suggested that patient accountability and withdrawals from
the study’s treatment phase should also be reported. Using
appropriate models, typically a linear model for a contin-
uous variable and a logistic regression for a binomial var-
iable, the effects of carryover, sequence site, baseline
variables, and prognostic variables should be tested.
0e data analysis of primary effectiveness endpoints in the
pivotal clinical studies for the APDS devices should be pri-
marily between-group comparison with respect to the primary
endpoints. 0e effects of the covariates must be adjusted
through appropriate statistical models, as long as these cova-
riates are found to confound the primary endpoints. 0e data
analysis of the secondary effectiveness endpoints is recom-
mended to be conducted through descriptive statistics. Data
analysis can be conducted through inferential statistics when
the sponsor intends to make labeling claims for any of the
endpoints. However, the sponsor must clearly specify the
hypothesis, statistical analysis, and success criteria on these
secondary endpoints in the study protocol. Multiplicity ad-
justment procedures for controlling the type 1 error rate should
be used (e.g., Bonferroni correction for controlling the fam-
ilywise error rate or Benjamini-Hochberg procedure for
controlling the false discovery rate).
In terms of performing hypothesis testing on endpoints’
effectiveness, it is typical that two populations are used:
Intention to Treat (ITT) population and the Per Protocol
(PP) population. For the analysis of primary endpoints, the
ITT population is widely preferred. 0e ITT population
should be composed of all randomized subjects, while the PP
population consists of all randomized subjects who complete
the treatment period without major protocol deviations.
0erefore, the sponsor must define the major protocol
deviations in the PP population with details in the study
protocol. It is also recommended that, in the study protocol,
the sponsor clearly states the hypothesis for each primary
endpoint and defines the overall success criteria of the study.
0e statistical plan for the pivotal clinical trial should be
defined in advance in the study protocol as well. If the study
is designed to assess either noninferiority or superiority with
a margin between the APDS and control groups, the sponsor
should propose and justify their noninferiority or superi-
ority margin prior to the beginning of their pivotal clinical
studies.
Although the missing data are usually inevitable in the
pivotal clinical trials, patient withdrawals and loss to follow-
ups should be minimized as much as possible while de-
signing the pivotal clinical trials and throughout the trials.
Missingness should be thoroughly documented with the
reason for missing and the specific treatment group. 0e
FDA recommended that, if there are missing data in primary
endpoints, they should be appropriately imputed in the ITT
population analysis. A sensitivity analysis, using not only
one but various methods, should be planned in the protocol
and conducted afterward to evaluate the impact of missing
data. 0e sensitivity analysis may include PP analysis and be
based upon last observation carried forward, multiple im-
putations, all missing as failures or success, worst-case
scenario, best case scenario, tipping point, and others [9].
For the data analysis of safety endpoints, descriptive
statistics of all adverse events should be presented for both
investigational studies and premarket submissions.0e FDA
recommends that the descriptive statistics of these sub-
groups should also be summarized. Furthermore, the safety
population for the pivotal study of an APDSmust include all
randomized subjects.
4. Design and Analysis of Clinical Trials for the
MiniMed 670G System
0e MiniMed 670G system, manufactured by Medtronic
(Medtronic Public Limited Company), is an artificial pan-
creas device system approved by the FDA on September 28,
2016. 0is system comprises five devices: MiniMed 670G
insulin pump, the Guardian Link (3) Transmitter, the
Guardian Sensor (3), One-Press Serter, and the Contour
NEXT Link 2.4 GlucoseMeter.0eMiniMed 670G system is
“intended for continuous delivery of basal insulin at user-
selectable rates and administration of insulin boluses in
user-selectable amounts for the management of type 1 di-
abetes in persons, fourteen years of age and older, requiring
insulin as well as for the continuous monitoring and
trending of glucose levels in the fluid under the skin.” 0e
MiniMed 670G system adopts “SmartGuard technology.”
Medtronic’s MiniMed 670G is considered to be the very first
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FDA-approved closed-loop, fully automated artificial pan-
creas device that allows computer programs to automatically
adjust delivery of basal insulin according to CGM sensor
glucose values and to “suspend delivery of insulin when the
sensor glucose value falls below or is predicted to fall below
predefined threshold values” [8].
Medtronic designed and performed two pivotal clinical
studies in the United States to demonstrate the safety and
effectiveness of the device for diabetes patients. One pivotal
study, Investigational Device Exemption or IDE G140053,
was a multicenter, prospective, single-sample correlational
study without any control group to evaluate the performance
measurement of the Guardian Sensor over 7 days. With
proper inclusion and exclusion criteria, this study enrolled a
total of 89 adolescents and adults with type 1 or type 2
diabetes mellitus between the ages of 14–75 years from 6
investigational sites. 0e subjects wore a receiver, the
Guardian Link Transmitter, and the Guardian Sensor for a 7-
day study period, during which each subject participated in a
three-day “frequent sample testing” in Day 1, Day 3, and Day
7. During these three days, intravenous blood samples were
obtained from the subjects every 5 to 15 minutes in a period
of approximately 12 to 14 hours. 0en, the samples were
analyzed for plasma blood glucose levels using the Yellow
Springs Instrument 2300 Stat Plus Glucose Lactate Analyzer,
referred to as the comparator method (CM). 0e subjects
were advised to continue with their previous diabetes reg-
imen to manage their diabetes instead of relying on the
investigational devices. 0e accuracy of the Guardian Sensor
was assessed by comparing the Guardian Sensor values to
the ones obtained from the CM.
To support the accuracy of the Guardian senor, de-
scriptive statistics were reported on percent difference of the
CGM values (using the Guardian Sensor) with respect to the
CM values, percent of the CGM values that fell within 15, 20,
30, 40, and >40mg/dL of the CM values, number and
percentage of the CM values collected while the CGM values
were less than 40mg/dL or greater than 400mg/dL, and
concurrence and agreement rate of the CGM values and the
CM values. Overall, these numerical results presented
substantial evidence to support the Guardian Sensor’s ac-
curacy in automatically adjusting basal insulin rates. In this
study, some subjects wore two Guardian Sensors. 0e
precision of the sensor system was assessed by comparing
sensor values to each other in these subjects. Data from two
parallel sensors provided 30,350 pairs of CGM measure-
ments with a mean percent absolute relative difference of
9.07% with a coefficient of variation of 6.5%.
Another pivotal clinical study (IDE G140167) was a
multicenter, single-arm, home and hotel clinical study to
evaluate the safety of the MiniMed 670G system and its
algorithm with the Guardian Sensor. 0is pivotal study
recruited 126 patients between the ages of 14 and 75, with
type 1 diabetes at 10 investigational sites. 0e subjects used
the 670G pump with the Guardian Link Transmitter, the
Guardian Sensor, and infusion sets for around 3.5 months.
0e study included a 2-week run-in period, a 3-month at
home use period, and a 5-day and 6-night hotel study during
month 1, 2, or 3 of the study. 0e device was instructed to be
used in the AutoMode for the entire 3months at home study
by the subjects.0is study was a descriptive study to evaluate
the safety of the MiniMed 670G system with the Auto Mode.
0erefore, there were no statistically powered endpoints in
the pivotal study, nor was there any hypothesis testing.
Although the effectiveness of the system was also assessed by
descriptive statistics on HbA1c level, the total daily dose of
insulin, time spent in Auto Mode versus time spent in
Manual Mode, time in different glucose range, time in the
hyperglycemic range, and so on without comparison to
alternative treatments, the emphasis of the study is still the
safety evaluation. Safety endpoints were serious adverse
events, serious adverse device events, unanticipated adverse
device effects, incidence of severe hypoglycemia, and inci-
dence of diabetic ketoacidosis. 0e results of the study
showed no reports of unanticipated adverse device effects,
no reports of diabetic ketoacidosis, and no reports of severe
hypoglycemia events. At the same time, there were 24 severe
hyperglycemia events reported. 0ere were four serious
adverse events reported of appendicitis, bacterial arthritis of
the right wrist, C. difficile diarrhea, and worsening rheu-
matoid arthritis. Furthermore, there were four procedure-
related adverse events: thrombophlebitis, pain, irritation or
bruising, and pain at the intravenous site.
5. Discussion and Conclusions
From a regulatory standpoint, this article reviews the FDA’s
recommendations on study design and data analysis of the
pivotal clinical trials for evaluating the safety and effec-
tiveness of an investigational APDS for automated regula-
tion of blood glucose levels of patients with type 1 diabetes.
While the statistical analysis is relatively standard in these
clinical trials [10], there are unique features for the selection
of patient population and clinical endpoints in study design
[6].
0e Juvenile Diabetes Research Foundation defined
three generations of nonclosed-loop and closed-loop APDSs
[7, 11]. An APDS is “closed-loop,” meaning that the system
is fully automated that integrates a CGM and an insulin
pump with a digital controller to achieve continuous
management of type 1 diabetes. First-generation APDSs are
nonclosed-loop, not fully automated systems with primary
functions of low-glucose suspend and predictive low- and
high-glucose suspend. Second-generation APDSs are auto-
mated insulin delivery systems. 0e early stage of the sec-
ond-generation APDSs is hybrid closed-loop devices at all
times with mealtime manual assist bolus, while the late stage
of the second-generation APDSs is fully automated insulin
delivery systems. 0ird-generation systems are fully auto-
mated multihormonal delivery devices. 0ese devices ad-
ministrate a secondary glucoregulatory hormone in addition
to insulin. 0e MiniMed 670G system is the first fully au-
tomated, second-generation APDS approved by the FDA
and commercially available on the United States market.
Second-generation APDSs are equipped with fully
automated insulin delivery and predictive low-glucose
management. Compared to the first-generation sensor-
augmented APDSs, patients can benefit from second-
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generation APDSs due to a potential improvement in
control of HbA1c values, less time and number of events
with hypoglycemia and hyperglycemia, and more time
within a normal range of sensor glucose. However, there
are still risks associated with the second-generation
APDSs’ full automation and predictive suspension: im-
proper suspension or decrease in insulin delivery due to
software error or erroneous CGM data or inappropriate
increase in insulin delivery or suggestions that patients
take additional insulin due to a software error or erro-
neous CGM data. As a result, hyperglycemia, ketosis,
ketoacidosis, or hypoglycemia may occur because of
erroneously willing or unwilling off label use of the device
or software malfunction. 0e risks with the predictive
low-glucose management are that the predictive suspend
feature may inappropriately suspend or resume insulin
due to a software defect or erroneous CGM data, which
inaccurately detects impending hypoglycemia or hypo-
glycemia. Yet, a first-of-its-kind second-generation
APDS, the MiniMed 670G system, was approved as the
FDA concluded its benefits outweigh its risks.
0e FDA approval of second-generation APDSs gives
patients and healthcare providers an opportunity for con-
tinuous glucose tracking and trending information that is
not feasible using traditional blood glucose monitoring.
Using the second-generation APDSs, patients and health-
care providers can now review the tracking and trending
data by time of day, such as daytime or nighttime, when
fewer finger sticks are conducted.
Because there were two first-generation APDSs devel-
oped by the samemanufacturer [12, 13], the designed pivotal
clinical trials for the MiniMed 670G system in its PMA
substantially deviated from the recommendations deliber-
ated in the APDS guidance [6]. While the sponsor closely
follows the FDA’s recommendations on evaluating the safety
of the device, the sponsor conducted a pivotal trial to
evaluate the diagnostic effectiveness of the system compared
to the CM with a single-arm observational study instead of a
two-group randomized controlled trial or cross-over trial.
0is reflects the flexibility of medical device clinical trials in
the regulatory process.
0e FDA guidance also presents suggestions for the
development of feasibility studies for the APDS systems [6].
While not all APDS systems need to go through feasibility
studies, these are designed to test specific aspects of the
APDS functionality and performance and to collect pre-
liminary data on safety. As feasibility studies aim to be
exploratory for device development and to support the
APDS functions without unexpected safety concerns, fea-
sibility studies are expected to have a short duration and
small patient population and to be descriptive. It is im-
perative that there are identifiable goals and prespecified
success criteria for feasibility studies. Future research on the
study design and data analysis of the clinical trials for in-
vestigational APDSs is not unique and should be in align-
ment with the pursuit of developing new methodologies and
designs in clinical trials. As a regulatory agency, the FDA
should pay attention to their regulation on the use of
observational studies for investigating the effectiveness and
safety of the APDSs.
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